Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine in MDD with Insomnia
NCT05978219Phase 4Completed
- Sponsor
- National Institute of Mental Health
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mirtazapine in major depressive disorder (MDD) and Insomnia, sponsored by National Institute of Mental Health. Primary endpoints: Hamilton Depression Rating Scale at 42 days and Insomnia Severity Index at 42 days. Started May 2023; status: completed.
02
Drugs
mirtazapine
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT05978219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978219.